tradingkey.logo

Pfizer’S Sasanlimab Combination Significantly Improves Event-Free Survival In Bcg-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

ReutersApr 26, 2025 6:03 PM

- Pfizer Inc PFE.N:

  • PFIZER’S SASANLIMAB COMBINATION SIGNIFICANTLY IMPROVES EVENT-FREE SURVIVAL IN BCG-NAÏVE, HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

  • PFIZER INC - PHASE 3 CREST TRIAL SHOWS 32% RISK REDUCTION WITH SASANLIMAB

  • PFIZER INC - RESULTS SHARED WITH GLOBAL HEALTH AUTHORITIES FOR REGULATORY FILINGS

  • PFIZER INC - TRIAL MEETS PRIMARY ENDPOINT WITH SASANLIMAB COMBINATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI